Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

476 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats.
Nishiyama A, Kobori H, Konishi Y, Morikawa T, Maeda I, Okumura M, Kishida M, Hamada M, Nagai Y, Nakagawa T, Ohashi N, Nakano D, Hitomi H, Imanishi M. Nishiyama A, et al. Among authors: imanishi m. J Pharmacol Exp Ther. 2010 Mar;332(3):1072-80. doi: 10.1124/jpet.109.158113. Epub 2009 Nov 25. J Pharmacol Exp Ther. 2010. PMID: 19940106 Free PMC article.
Angiotensin II receptor blockade reduces salt sensitivity of blood pressure through restoration of renal nitric oxide synthesis in patients with diabetic nephropathy.
Imanishi M, Okada N, Konishi Y, Morikawa T, Maeda I, Kitabayashi C, Masada M, Shirahashi N, Wilcox CS, Nishiyama A. Imanishi M, et al. J Renin Angiotensin Aldosterone Syst. 2013 Mar;14(1):67-73. doi: 10.1177/1470320312454764. Epub 2012 Aug 2. J Renin Angiotensin Aldosterone Syst. 2013. PMID: 22859713 Free article. Clinical Trial.
Regression of glomerular and tubulointerstitial injuries by dietary salt reduction with combination therapy of angiotensin II receptor blocker and calcium channel blocker in Dahl salt-sensitive rats.
Rafiq K, Nishiyama A, Konishi Y, Morikawa T, Kitabayashi C, Kohno M, Masaki T, Mori H, Kobori H, Imanishi M. Rafiq K, et al. Among authors: imanishi m. PLoS One. 2014 Sep 18;9(9):e107853. doi: 10.1371/journal.pone.0107853. eCollection 2014. PLoS One. 2014. PMID: 25233358 Free PMC article.
Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria.
Nishiyama A, Nakagawa T, Kobori H, Nagai Y, Okada N, Konishi Y, Morikawa T, Okumura M, Meda I, Kiyomoto H, Hosomi N, Mori T, Ito S, Imanishi M. Nishiyama A, et al. Among authors: imanishi m. J Hypertens. 2008 Sep;26(9):1849-59. doi: 10.1097/HJH.0b013e3283060efa. J Hypertens. 2008. PMID: 18698221 Free PMC article.
Evidence for abundant presence of chymase-positive mast cells in the kidneys of patients with immunoglobulin A nephropathy: effect of combination therapy with prednisolone and angiotensin II receptor blocker valsartan.
Konishi Y, Morikawa T, Okada N, Maeda I, Kitabayashi C, Yoshioka K, Okumura M, Nishiyama A, Ueda M, Takai S, Miyazaki M, Imanishi M. Konishi Y, et al. Among authors: imanishi m. Hypertens Res. 2008 Aug;31(8):1517-24. doi: 10.1291/hypres.31.1517. Hypertens Res. 2008. PMID: 18971525 Clinical Trial.
Predictive significance of kidney myeloid-related protein 8 expression in patients with obesity- or type 2 diabetes-associated kidney diseases.
Kuwabara T, Mori K, Kasahara M, Yokoi H, Imamaki H, Ishii A, Koga K, Sugawara A, Yasuno S, Ueshima K, Morikawa T, Konishi Y, Imanishi M, Nishiyama A, Nakao K, Mukoyama M. Kuwabara T, et al. Among authors: imanishi m. PLoS One. 2014 Feb 18;9(2):e88942. doi: 10.1371/journal.pone.0088942. eCollection 2014. PLoS One. 2014. PMID: 24558454 Free PMC article.
476 results